Developer docs
API playgroundTry for free, no card

Search company profiles

Mayne Pharma

Full company profile

uuid000sszc

Namestring
Mayne Pharma
Legal namestring
Mayne Pharma Group Limited
Websiteurl
maynepharma.com
Company typeenum
Public
Founded yearint
1980
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSalisbury, Australia
HQ citystring
Salisbury
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, drug delivery technologies, contract manufacturing services, women's health medications, dermatology treatments
Industry5 codes
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code5 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Specialty Pharmaceutical Product Sales
TypeOne Time License
Description

Mayne Pharma generates revenue primarily through the sale of branded and generic pharmaceuticals in the US and Australia, including women's health products (contraceptives, menopause treatments) and dermatology products (treatments for psoriasis, acne, rosacea). Products are sold through direct-to-patient channels (DistributeRx) and traditional wholesale/distribution channels.

maynepharma.com
2Contract Development and Manufacturing (CDMO Services)
TypeProfessional Services
Description

Mayne Pharma operates a full-service contract development and manufacturing organisation (CDMO) providing pharmaceutical development, analytical testing, and commercial manufacturing services to clients worldwide. Revenue is generated through service fees for development and manufacturing.

maynepharma.com
3Out-licensing and In-licensing Royalties
TypeLicensing Royalties
Description

Mayne Pharma develops partnerships for global marketing of products developed in-house, receiving licensing fees and royalties from international partners for products including LOZANOC®/TOLSURA®, KAPANOL®, ERYC®, and ASTRIX® marketed in various countries.

maynepharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
Pricing details2 tiers
1DistributeRx receives structured fixed fees per prescription filled under distribution partnership agreements
ModelUsage-basedBilling cadencePay-as-you-go
Notes

DistributerRx receives structured fixed fees per prescription filled through its digital prescription distribution platform under the exclusive distribution partnership with Resilia Pharmaceuticals for RECEDO topical gel.

grafa.com
2Direct-to-patient prescription pricing through Adelaide Apothecary cash-pay channel
ModelOtherBilling cadencePay-as-you-go
Notes

Approximately 70-80% of prescriptions expected to flow through the cash-pay Adelaide channel. The cash-pay pharmaceutical market is projected to reach $252 billion by 2030. 59% of volume went through non-wholesale channels in first half fiscal 2026.

seekingalpha.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Adelaide Apothecary
Description

Pharmacy licensed in all 50 US states supporting the DistributeRx direct-to-patient model

maynepharma.com
+2 more records
Core offering1 text field

Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops, manufactures, and commercializes branded and generic prescription drugs across women's health, dermatology, infectious disease, and pain management. The company applies proprietary oral and topical drug delivery technologies (SUBA®, Pellet, CLEANTASTE®, Controlled Release) to enhance bioavailability and patient outcomes, operates a direct-to-patient distribution platform (DistributeRx) in the US, and provides CDMO contract development and manufacturing services globally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • H1 FY26 gross margin improved to 65.3%, up 390 basis points, driven by strategic shift toward higher-margin dermatology products and direct-to-patient channels
+2 more records
Product overview1 text field

Mayne Pharma is a specialty pharmaceutical company with a diversified portfolio spanning Women's Health, Dermatology, and Infectious Disease therapeutic areas. The company's product offerings include branded prescription drugs (such as ANNOVERA®, BIJUVA®, IMVEXXY®, DORYX®, LEXETTE®, RHOFADE®) and generic pharmaceuticals, supported by proprietary drug delivery technologies including SUBA® bioavailability enhancement, Pellet Technology, CLEANTASTE® taste masking, and Controlled Release Delivery Systems. The company operates DistributeRx, a direct-to-patient distribution platform, and provides CDMO contract manufacturing services. Products are commercialized in the US, Australia, and international markets through strategic partnerships.

Product and service23 records
1ANNOVERA® Vaginal System
CategoryWomen's Health - Contraception
Description

Segesterone Acetate and Ethinyl Estradiol Vaginal System providing sustained-release contraception over multiple cycles; targeted at women in the US seeking long-acting hormonal contraception.

2BIJUVA® Capsules (1 mg/100 mg)
CategoryWomen's Health - Menopause Therapy
Description

Estradiol and Progesterone Capsules for menopausal hormone therapy, providing bioidentical hormone replacement for women experiencing menopausal symptoms.

3BIJUVA® Capsules (0.5 mg/100 mg)
CategoryWomen's Health - Menopause Therapy
Description

Lower-dose Estradiol and Progesterone Capsules for menopausal hormone therapy, providing bioidentical hormone replacement.

4IMVEXXY® Vaginal Inserts (10 mcg)
CategoryWomen's Health - Menopause Therapy
Description

Estradiol Vaginal Insert (10 mcg) for treatment of dyspareunia due to vulvar and vaginal atrophy in menopausal women.

5IMVEXXY® Vaginal Inserts (4 mcg)
CategoryWomen's Health - Menopause Therapy
Description

Estradiol Vaginal Insert (4 mcg) for treatment of dyspareunia due to vulvar and vaginal atrophy in menopausal women.

6NEXTSTELLIS® Tablets
CategoryWomen's Health - Contraception
Description

Drospirenone and Estetrol Tablets (3 mg/14.2 mg) for oral contraception using a novel estrogen component; available in the US and Australia.

7SOLTAMOX® Oral Solution
CategoryWomen's Health - Oncology
Description

Tamoxifen Citrate Oral Solution for treatment of breast cancer, providing a liquid alternative to tablet formulations.

8DORYX® MPC Delayed-Release Tablets
CategoryDermatology - Acne
Description

Doxycycline Hyclate Delayed-Release Tablets, 60 mg for acne treatment using proprietary pellet technology.

9DORYX® Delayed-Release Tablets (200 mg)
CategoryDermatology - Acne/Infections
Description

Doxycycline Hyclate Delayed-Release Tablets, 200 mg for acne and bacterial infections, leveraging pellet technology.

10FABIOR® Foam
CategoryDermatology - Acne
Description

Tazarotene Foam, 0.1% for topical treatment of acne vulgaris.

11LEXETTE® Topical Foam
CategoryDermatology - Psoriasis
Description

Halobetasol Propionate Topical Foam, 0.05% for treatment of plaque psoriasis.

12RHOFADE® Cream
CategoryDermatology - Rosacea
Description

Oxymetazoline Hydrochloride Cream, 1% for topical treatment of persistent facial erythema associated with rosacea.

13SORILUX® Foam
CategoryDermatology - Psoriasis
Description

Calcipotriene Foam, 0.005% for treatment of plaque psoriasis.

14WYNZORA® Cream
CategoryDermatology - Psoriasis
Description

Calcipotriene and Betamethasone Dipropionate Cream for treatment of plaque psoriasis.

15EPSOLAY® Cream
CategoryDermatology - Rosacea
Description

Benzoyl Peroxide Cream, 5% 30g Pump for treatment of rosacea.

16TWYNEO® Cream
CategoryDermatology - Acne
Description

Tretinoin and Benzoyl Peroxide Cream, 0.1%/3% for treatment of acne vulgaris.

17TOLSURA® Capsules
CategoryInfectious Disease - Antifungal
Description

SUBA®-Itraconazole Capsules, 65 mg using proprietary SUBA bioavailability technology for enhanced antifungal absorption; marketed in the US.

18LOZANOC® / TOLSURA® Capsules (Rest of World)
CategoryInfectious Disease - Antifungal
Description

Orally administered antifungal agent using SUBA technology with approximately double the bioavailability of conventional itraconazole formulations; marketed internationally through licensing partners.

19ERYC® Capsules
CategoryInfectious Disease - Antibiotic
Description

Delayed-release erythromycin using proprietary pellet technology, protecting the drug from stomach acid for optimal intestinal absorption.

20KAPANOL® Capsules
CategoryPain Management
Description

Sustained-release morphine sulfate capsules (10 mg, 20 mg, 50 mg, 100 mg) for management of moderate to severe chronic pain.

21ASTRIX® Capsules
CategoryCardiovascular
Description

Enteric-coated pelletized low-dose aspirin for prevention of heart attack and stroke, reducing stomach irritation compared to immediate-release aspirin.

22DistributeRx
CategoryDistribution Platform
Description

Direct-to-patient pharmaceutical distribution platform bypassing intermediaries, utilizing Adelaide Apothecary pharmacy (licensed in all 50 US states) and contracted specialty pharmacies; approximately 70-80% of prescriptions expected through cash-pay Adelaide channel.

23CDMO Contract Development and Manufacturing Services
CategoryContract Manufacturing Services
Description

Full-service contract development and manufacturing organization specializing in novel oral and topical dose forms, providing pharmaceutical development, analytical testing, and commercial manufacturing services to clients worldwide.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-01
Description

DistributerRx (wholly-owned subsidiary of Mayne Pharma) secured an exclusive distribution partnership with Atlanta-based Resilia Pharmaceuticals to distribute RECEDO topical gel across the United States. DistributerRx leverages its digital prescription distribution platform and receives structured fixed fees per prescription filled. The partnership targets specialist healthcare prescribers in plastic surgery and OB/GYN practices for advanced scar care.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships of products developed in-house.

3ISDIN
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships.

maynepharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships.

5Gedeon Richter (formerly Mithra)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships.

maynepharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as an existing partner in Mayne Pharma's partnering philosophy.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as an existing partner in Mayne Pharma's partnering philosophy.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as an existing partner. TherapeuticsMD reported license revenue surging 71.6% to $3.0 million primarily driven by sales of licensed products under the Mayne License Agreement, with $7.5 million cash as of December 31, 2025.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as an existing partner in Mayne Pharma's partnering philosophy.

10Sandoz
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as an existing partner in Mayne Pharma's partnering philosophy.

maynepharma.com
11Mc2
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as an existing partner in Mayne Pharma's partnering philosophy.

12CoAssist
Strategic tierCoreTypeTechnology or Integration
Description

Vendor partner for benefits verification in the DistributeRx direct-to-patient distribution model. CoAssist supports the digital prescription platform by verifying patient insurance benefits.

seekingalpha.com
13International Licensing Partners (Argentina, Austria, Germany, Israel, Italy, Mexico, Spain, Middle East)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Mayne Pharma has established international partners for LOZANOC®/TOLSURA® in Argentina, Austria, Germany, Israel, Italy, Mexico, Spain, and the Middle East for out-licensing of products developed in-house.

maynepharma.com
14KAPANOL® International Partners (Thailand, Canada, Switzerland, Germany, Austria, Slovenia, Bulgaria)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

KAPANOL® capsules are partnered internationally in Thailand, Canada, Switzerland, Germany, Austria, Slovenia, Bulgaria with options to extend in the rest of Europe and the United Kingdom.

maynepharma.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large global CDMO offering oral, injectable and biologic manufacturing services. Comparable to Mayne Pharma Services in CDMO scope but with much broader capabilities and client base.

TypeBroad incumbent
Description

Integrated CDMO providing drug substance through commercial manufacturing for small molecules and biologics. Comparable to Mayne in offering development and commercial-scale manufacturing under one roof.

TypeBroad incumbent
Description

Global leader in generic and specialty pharmaceuticals with substantial women's health and dermatology portfolios. Comparable in specialty/generic mix and CDMO-adjacent manufacturing scale.

TypeDirect peer
Description

Specialty generics and OTC pharmaceutical company with broad dermatology presence. Comparable to Mayne in combining generic and branded dermatology franchises.

TypeDirect peer
Description

Women's health specialty pharma commercialising ANNOVERA, BIJUVA and IMVEXXY (licensed from Mayne). Directly comparable in US women's reproductive and menopause product portfolio.

6Endo International
TypeBroad incumbent
Description

Specialty pharma with diversified portfolio across branded, sterile injectables and generics. Comparable in operating a specialty-focused model with US commercial scale.

TypeDirect peer
Description

Mid-sized CDMO specialising in oral solid dose development and manufacturing with proprietary particle engineering platforms. Closely comparable to Mayne's CDMO business in scale and dose-form focus.

TypeBroad incumbent
Description

Canadian generic pharmaceutical manufacturer with diversified portfolio and in-house development. Comparable in scale and generic/specialty combination, though primarily Canadian-headquartered.

TypeRegional player
Description

South Africa-based specialty and generic pharma with strong emerging-market franchise. Comparable in specialty pharma focus and global partnership approach, though geographically different.

TypeDirect peer
Description

US specialty generics company that pursued Mayne's acquisition. Most directly comparable US specialty generics peer with overlapping portfolio and CDMO-style manufacturing capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mayne Pharma

Specialty Pharmaceuticalsmaynepharma.com

Mayne Pharma firmographics

Firmographics
Name
Mayne Pharma
Legal name
Mayne Pharma Group Limited
Website
https://maynepharma.com
Company type
Public
Founded year
1980
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Where Mayne Pharma is headquartered

Location

Headquarters

HQ city
Salisbury
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

Mayne Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Specialty Pharmaceutical Product Sales: Mayne Pharma generates revenue primarily through the sale of branded and generic pharmaceuticals in the US and Australia, including women's health products (contraceptives, menopause treatments) and dermatology products (treatments for psoriasis, acne, rosacea). Products are sold through direct-to-patient channels (DistributeRx) and traditional wholesale/distribution channels.
  2. Contract Development and Manufacturing (CDMO Services): Mayne Pharma operates a full-service contract development and manufacturing organisation (CDMO) providing pharmaceutical development, analytical testing, and commercial manufacturing services to clients worldwide. Revenue is generated through service fees for development and manufacturing.
  3. Out-licensing and In-licensing Royalties: Mayne Pharma develops partnerships for global marketing of products developed in-house, receiving licensing fees and royalties from international partners for products including LOZANOC®/TOLSURA®, KAPANOL®, ERYC®, and ASTRIX® marketed in various countries.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goDistributeRx receives structured fixed fees per prescription filled under distribution partnership agreements
OtherPay-as-you-goDirect-to-patient prescription pricing through Adelaide Apothecary cash-pay channel

Go-to-market motion4 records

Distribution channels4 records

Marketing channels5 records

Mayne Pharma product offering

Product offering

Core offering

Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops, manufactures, and commercializes branded and generic prescription drugs across women's health, dermatology, infectious disease, and pain management. The company applies proprietary oral and topical drug delivery technologies (SUBA®, Pellet, CLEANTASTE®, Controlled Release) to enhance bioavailability and patient outcomes, operates a direct-to-patient distribution platform (DistributeRx) in the US, and provides CDMO contract development and manufacturing services globally.

Product overview

Mayne Pharma is a specialty pharmaceutical company with a diversified portfolio spanning Women's Health, Dermatology, and Infectious Disease therapeutic areas. The company's product offerings include branded prescription drugs (such as ANNOVERA®, BIJUVA®, IMVEXXY®, DORYX®, LEXETTE®, RHOFADE®) and generic pharmaceuticals, supported by proprietary drug delivery technologies including SUBA® bioavailability enhancement, Pellet Technology, CLEANTASTE® taste masking, and Controlled Release Delivery Systems. The company operates DistributeRx, a direct-to-patient distribution platform, and provides CDMO contract manufacturing services. Products are commercialized in the US, Australia, and international markets through strategic partnerships.

Differentiator

Problem solved

Functional benefit

Brands

  • Adelaide Apothecary: Pharmacy licensed in all 50 US states supporting the DistributeRx direct-to-patient model
  • DistributeRx
  • Mayne Pharma Services

Products and services

  • ANNOVERA® Vaginal System Segesterone Acetate and Ethinyl Estradiol Vaginal System providing sustained-release contraception over multiple cycles; targeted at women in the US seeking long-acting hormonal contraception.
  • BIJUVA® Capsules (1 mg/100 mg) Estradiol and Progesterone Capsules for menopausal hormone therapy, providing bioidentical hormone replacement for women experiencing menopausal symptoms.
  • BIJUVA® Capsules (0.5 mg/100 mg) Lower-dose Estradiol and Progesterone Capsules for menopausal hormone therapy, providing bioidentical hormone replacement.
  • IMVEXXY® Vaginal Inserts (10 mcg) Estradiol Vaginal Insert (10 mcg) for treatment of dyspareunia due to vulvar and vaginal atrophy in menopausal women.
  • IMVEXXY® Vaginal Inserts (4 mcg) Estradiol Vaginal Insert (4 mcg) for treatment of dyspareunia due to vulvar and vaginal atrophy in menopausal women.
  • NEXTSTELLIS® Tablets Drospirenone and Estetrol Tablets (3 mg/14.2 mg) for oral contraception using a novel estrogen component; available in the US and Australia.
  • SOLTAMOX® Oral Solution Tamoxifen Citrate Oral Solution for treatment of breast cancer, providing a liquid alternative to tablet formulations.
  • DORYX® MPC Delayed-Release Tablets Doxycycline Hyclate Delayed-Release Tablets, 60 mg for acne treatment using proprietary pellet technology.
  • DORYX® Delayed-Release Tablets (200 mg) Doxycycline Hyclate Delayed-Release Tablets, 200 mg for acne and bacterial infections, leveraging pellet technology.
  • FABIOR® Foam Tazarotene Foam, 0.1% for topical treatment of acne vulgaris.
  • LEXETTE® Topical Foam Halobetasol Propionate Topical Foam, 0.05% for treatment of plaque psoriasis.
  • RHOFADE® Cream Oxymetazoline Hydrochloride Cream, 1% for topical treatment of persistent facial erythema associated with rosacea.
  • SORILUX® Foam Calcipotriene Foam, 0.005% for treatment of plaque psoriasis.
  • WYNZORA® Cream Calcipotriene and Betamethasone Dipropionate Cream for treatment of plaque psoriasis.
  • EPSOLAY® Cream Benzoyl Peroxide Cream, 5% 30g Pump for treatment of rosacea.
  • TWYNEO® Cream Tretinoin and Benzoyl Peroxide Cream, 0.1%/3% for treatment of acne vulgaris.
  • TOLSURA® Capsules SUBA®-Itraconazole Capsules, 65 mg using proprietary SUBA bioavailability technology for enhanced antifungal absorption; marketed in the US.
  • LOZANOC® / TOLSURA® Capsules (Rest of World) Orally administered antifungal agent using SUBA technology with approximately double the bioavailability of conventional itraconazole formulations; marketed internationally through licensing partners.
  • ERYC® Capsules Delayed-release erythromycin using proprietary pellet technology, protecting the drug from stomach acid for optimal intestinal absorption.
  • KAPANOL® Capsules Sustained-release morphine sulfate capsules (10 mg, 20 mg, 50 mg, 100 mg) for management of moderate to severe chronic pain.
  • ASTRIX® Capsules Enteric-coated pelletized low-dose aspirin for prevention of heart attack and stroke, reducing stomach irritation compared to immediate-release aspirin.
  • DistributeRx Direct-to-patient pharmaceutical distribution platform bypassing intermediaries, utilizing Adelaide Apothecary pharmacy (licensed in all 50 US states) and contracted specialty pharmacies; approximately 70-80% of prescriptions expected through cash-pay Adelaide channel.
  • CDMO Contract Development and Manufacturing Services Full-service contract development and manufacturing organization specializing in novel oral and topical dose forms, providing pharmaceutical development, analytical testing, and commercial manufacturing services to clients worldwide.

Quantifiable outcome

  • H1 FY26 gross margin improved to 65.3%, up 390 basis points, driven by strategic shift toward higher-margin dermatology products and direct-to-patient channels
  • +2 more outcomes

Companies that use Mayne Pharma

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Mayne Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Mayne Pharma partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • Resilia PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 June 2026DistributerRx (wholly-owned subsidiary of Mayne Pharma) secured an exclusive distribution partnership with Atlanta-based Resilia Pharmaceuticals to distribute RECEDO topical gel across the United States. DistributerRx leverages its digital prescription distribution platform and receives structured fixed fees per prescription filled. The partnership targets specialist healthcare prescribers in plastic surgery and OB/GYN practices for advanced scar care.
  • BoryungminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships of products developed in-house.
  • ISDINminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships.
  • GaldermaminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships.
  • Gedeon Richter (formerly Mithra)minorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy for global marketing partnerships.
  • ViatrisminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy.
  • LipomedminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy.
  • TXMD (TherapeuticsMD)minorStrategic or Co-development PartnerListed as an existing partner. TherapeuticsMD reported license revenue surging 71.6% to $3.0 million primarily driven by sales of licensed products under the Mayne License Agreement, with $7.5 million cash as of December 31, 2025.
  • Upsher-SmithminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy.
  • SandozminorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy.
  • Mc2minorStrategic or Co-development PartnerListed as an existing partner in Mayne Pharma's partnering philosophy.
  • CoAssistcoreTechnology or IntegrationVendor partner for benefits verification in the DistributeRx direct-to-patient distribution model. CoAssist supports the digital prescription platform by verifying patient insurance benefits.
  • International Licensing Partners (Argentina, Austria, Germany, Israel, Italy, Mexico, Spain, Middle East)minorChannel Partner/ Reseller/ DistributorMayne Pharma has established international partners for LOZANOC®/TOLSURA® in Argentina, Austria, Germany, Israel, Italy, Mexico, Spain, and the Middle East for out-licensing of products developed in-house.
  • KAPANOL® International Partners (Thailand, Canada, Switzerland, Germany, Austria, Slovenia, Bulgaria)minorChannel Partner/ Reseller/ DistributorKAPANOL® capsules are partnered internationally in Thailand, Canada, Switzerland, Germany, Austria, Slovenia, Bulgaria with options to extend in the rest of Europe and the United Kingdom.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Mayne Pharma competitors and assessment

Company assessment

Broad incumbents

  • Catalent: Large global CDMO offering oral, injectable and biologic manufacturing services. Comparable to Mayne Pharma Services in CDMO scope but with much broader capabilities and client base.
  • Patheon (Thermo Fisher Scientific): Integrated CDMO providing drug substance through commercial manufacturing for small molecules and biologics. Comparable to Mayne in offering development and commercial-scale manufacturing under one roof.
  • Teva Pharmaceutical Industries: Global leader in generic and specialty pharmaceuticals with substantial women's health and dermatology portfolios. Comparable in specialty/generic mix and CDMO-adjacent manufacturing scale.
  • Endo International: Specialty pharma with diversified portfolio across branded, sterile injectables and generics. Comparable in operating a specialty-focused model with US commercial scale.
  • Apotex: Canadian generic pharmaceutical manufacturer with diversified portfolio and in-house development. Comparable in scale and generic/specialty combination, though primarily Canadian-headquartered.

Direct peers

  • Perrigo Company: Specialty generics and OTC pharmaceutical company with broad dermatology presence. Comparable to Mayne in combining generic and branded dermatology franchises.
  • TherapeuticsMD: Women's health specialty pharma commercialising ANNOVERA, BIJUVA and IMVEXXY (licensed from Mayne). Directly comparable in US women's reproductive and menopause product portfolio.
  • Hovione: Mid-sized CDMO specialising in oral solid dose development and manufacturing with proprietary particle engineering platforms. Closely comparable to Mayne's CDMO business in scale and dose-form focus.
  • Cosette Pharmaceuticals: US specialty generics company that pursued Mayne's acquisition. Most directly comparable US specialty generics peer with overlapping portfolio and CDMO-style manufacturing capabilities.

Regional players

  • Aspen Pharmacare: South Africa-based specialty and generic pharma with strong emerging-market franchise. Comparable in specialty pharma focus and global partnership approach, though geographically different.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Mayne Pharma social profiles

Digital presence

Mayne Pharma compliance and trust

Trust signal

Compliance9 records

Mayne Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mayne Pharma leadership team

Management profile

Number of profiles

Profiles7 records

Mayne Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Mayne Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mayne Pharma M&A and investment

M&A and investment

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mayne Pharma

What does Mayne Pharma do?

Mayne Pharma is an ASX-listed specialty pharmaceutical company that develops, manufactures, and commercializes branded and generic prescription drugs across women's health, dermatology, infectious disease, and pain management. The company applies proprietary oral and topical drug delivery technologies (SUBA®, Pellet, CLEANTASTE®, Controlled Release) to enhance bioavailability and patient outcomes, operates a direct-to-patient distribution platform (DistributeRx) in the US, and provides CDMO contract development and manufacturing services globally.

Is Mayne Pharma a public or private company?

Mayne Pharma is a public company. It is classified as public and is currently operating.

When was Mayne Pharma founded?

Mayne Pharma was founded in 1980. It employs 101 to 250 people.

Where is Mayne Pharma based?

Mayne Pharma is headquartered in Salisbury, Australia, in the Oceania region.

How does Mayne Pharma make money?

Three revenue lines are on record. Specialty Pharmaceutical Product Sales are the primary driver. The others are contract Development and Manufacturing (CDMO Services) and out-licensing and In-licensing Royalties.

Who are Mayne Pharma's main competitors?

Broad incumbents on record are Catalent, Patheon (Thermo Fisher Scientific), Teva Pharmaceutical Industries, Endo International and Apotex. Direct peers are Perrigo Company, TherapeuticsMD, Hovione and Cosette Pharmaceuticals. Aspen Pharmacare is listed as a regional player.

Does Mayne Pharma have an API?

No public API is recorded for Mayne Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate헝가리 게데온 리히터, 호주 메인파마 4억800만 달러에 인수 추진 : 네이트 뉴스Hungarian pharmaceutical giant Gedeon Richter agreed to acquire Australian firm Mayne Pharma for about $480 million, causing Mayne's stock to surge 86% to $5.97. The deal, valued at $640 million, requires shareholder and regulatory approval, with completion expected by mid-2027.Investing.comMayne Pharma shares surge on $407 mln takeover offer from Gedeon RichterMayne Pharma agreed to be acquired by Gedeon Richter for A$604 million, paying A$6.40 per share, a 99.4% premium. Shares surged 86.3% to A$5.98. The deal is subject to regulatory and shareholder approvals, with a shareholder vote expected in late January 2027 and completion targeted for March.Investing.comMayne Pharma shares surge on $407 mln takeover offer from Gedeon RichterMayne Pharma agreed to be acquired by Gedeon Richter for A$604 million, paying A$6.40 per share, a 99.4% premium. Shares surged 86.3% to A$5.98. The deal is subject to regulatory and shareholder approvals, with a shareholder vote expected in late January 2027 and completion targeted for March.Investing.comWhy is Mayne Pharma stock surging today?Mayne Pharma stock surged nearly 81% to A$5.805 after Gedeon Richter agreed to acquire all outstanding shares at A$6.40 cash per share, valuing the company at about A$604 million. The offer is a 99.4% premium to the last closing price and 124% to the 30-day volume-weighted average, with major shareholders supporting the deal.The future of tradingAustralia's Mayne Pharma surges on $408 million takeover by Hungary's Gedeon RichterMayne Pharma shares surged up to 86% to A$5.970 after Gedeon Richter entered a takeover scheme to buy 100% of the company. The offer values equity at about A$604 million, a 99.4% premium to the last close, subject to selling its international business to Evaris Pharma.Dealroom.coGedeon Richter to buy Mayne Pharma in US$390.8M cash deal at 99% premium | Dealroom NewsGedeon Richter agreed to acquire ASX-listed Mayne Pharma for US$4.14 per share in cash, valuing the company at about US$390.8M. The deal represents a 99.4% premium to Mayne's November 16 close, with shareholders representing 22.14% voting in favor. Implementation is targeted for early 2027.TradingViewMayne Pharma Agrees to $604m Takeover Proposal from Gedeon RichterMayne Pharma agreed to a $604 million cash takeover by Gedeon Richter, offering $6.40 per share, a 99.4% premium to the closing price. The deal depends on completing the sale of its International business to Evaris Pharma and obtaining regulatory approvals. Shareholder voting is scheduled for late January 2027.The future of tradingAustralia's Mayne Pharma accepts $408 million bid from Gedeon RichterMayne Pharma accepted a $408 million bid from Gedeon Richter, valuing the deal at about A$604 million. Gedeon Richter offered A$6.40 per Mayne share. The acquisition was agreed on Tuesday.Mirage NewsMayne Pharma Sells Australian Operations for $55.5MMayne Pharma sold its Australian and international commercial operations, including contract development and manufacturing, for $55.5 million. The divestment is part of its transition to a US-focused specialty pharmaceutical company. The deal is subject to ACCC approval and expected to complete in early 2027.Seeking AlphaMayne Pharma Group Limited (MAYNF) M&A Call TranscriptMayne Pharma announced a binding agreement to sell its Australian manufacturing and commercial business, MPI, to Evaris Pharma for $55.5 million in cash. The deal, valued at 0.79x MPI's FY26 revenue of $70.7 million, is expected to close in Q3 FY27 and is not subject to FIRB approval or financing conditions.